Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002271 · ClinicalTrials.gov registry record · NA

An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects

A NA study of HIV Infections, sponsored by Lederle Laboratories.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002271: Completed NA study of HIV Infections, sponsored by Lederle Laboratories.

NCT00002271 is a NA study of HIV Infections that has completed, run by Lederle Laboratories. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002271, a NA study of HIV Infections, has completed, sponsored by Lederle Laboratories.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

To characterize the pharmacokinetics of orally administered 3'-deoxy-3'-fluorothymidine (FLT), in a liquid formulation, after single doses in asymptomatic HIV-infected patients and to assess the safety and tolerance of the single oral doses of FLT.

Conditions Studied

HIV Infections

Interventions

  • DRUG Alovudine

Study Locations (1)

Maryland

  • Johns Hopkins Hosp - Baltimore

Trial Details

FieldValue
Phase NA
Lederle Laboratories

6 total trials

What the finished NCT00002271 record still lists

NCT00002271 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Alovudine is the first listed.

NCT00002271 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00002271 about?

NCT00002271 is a clinical study titled "An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects". To characterize the pharmacokinetics of orally administered 3'-deoxy-3'-fluorothymidine (FLT), in a liquid formulation, after single doses in asymptomatic HIV-infected patients and to assess the safety and tolerance of the single oral doses of FLT.

What is the current status of trial NCT00002271?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002271 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002271?

The interventions under investigation include: Alovudine (DRUG).

Who is sponsoring clinical trial NCT00002271?

This trial is sponsored by Lederle Laboratories, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002271 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002271, the US trial registry maintained by the National Library of Medicine. NCT00002271 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.